AKT1 and prostate cancer: mTOR inhibitors for prostate cancer patients with TSC1 (tuberous sclerosis complex 1) mutations and concomitant targeting of PI3K and MEK represent approaches to block PI3K/AKT/mTOR pathway (Carneiro et al., 2015[7]).